Therapeutic drug monitoring vs. pharmacogenetic testing in the context of elevated olanzapine concentrations and prior clozapine intolerability: a case study
Abstract Background Strong evidence for therapeutic drug monitoring exists for olanzapine and clozapine, however, olanzapine therapeutic drug monitoring is often underutilized. Evidence for pharmacogenomic-guided dosing of antipsychotics is not as robust, especially for cytochrome P450 1A2 metaboliz...
Guardat en:
| Autors principals: | , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMC
2024-12-01
|
| Col·lecció: | BMC Psychiatry |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1186/s12888-024-06319-5 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|